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The macroscopic as well as the corresponding histopatho-
logical examination findings are shown in the Electronic 
Supplementary Material Table 6 of the publication by 
Zeljenková et al. (2014).
2. Testbiotech states that Zeljenková et al. (2014) “dis-
miss the toxicological relevance of the observed lower 
levels of total protein in serum (TP)”.
Response The TP level was significantly lower in the 
serum of male rats fed the 11 % GMO and 33 % GMO diet 
in the feeding trial A and in that of female rats fed the 33 % 
GMO diet in the feeding trial B if compared to the corre-
sponding control animals. When assessing the biological/
toxicological relevance of these above-mentioned results, 
one must take into account:
I. No such decreases were observed in the female rats fed 
the 11 % GMO and 33 % GMO diets in the feeding 
trial A, as well as in the male rats fed the 11 % GMO 
and 33 % GMO diet in the feeding trial B. The changes 
in TP are therefore inconsistent across the various 
groups and treatments. It should be noted that in both 
trials A and B genetically modified maize with the 
same GMO event (MON810) had been used. Moreo-
ver, a significantly lower total protein level in serum 
was also observed in female rats of study B fed the 
conventional maize DKC6815 at a 33 % level.
II. If the decrease of the serum protein levels were as rel-
evant, as Bauer-Panskus and Then (2014) state, one 
would have expected that this decrease had an impact 
on the growth of the young animals used in these feed-
ing trials. However, there were no significant body 
weight differences between rats fed the GMO diets and 
rats fed the control diets.
Dear Editors,
This letter is sent in response to a report and press release 
dated 7 November 2014 by Bauer-Panskus and Then (2014) 
which was issued on the website of TESTBIOTECH e.V. 7 
November 2014. The authors criticize the presentation and 
interpretation of the results of recently published 90-day 
feeding studies with diets containing genetically modified 
MON810-maize varieties and their comparators (Zeljen-
ková et al. 2014), which was performed within the EU-
funded GRACE project. In the following paragraphs, we 
reply point-by-point to the criticisms raised:
1. Bauer-Panskus and Then claim: “The GLP-controlled 
90-day feeding study in Han Wistar RCC rats aimed 
at providing a safety evaluation of two varieties of 
MON810 as a dietary admixture of 11 % (low dose) 
or 33 % (high dose). The authors claim to have fol-
lowed “the guidance for such studies published by the 
EFSA Scientific Committee in 2011 and the OECD 
Test Guideline 408”. Although this is generally true, it 
needs to be stated that it is not entirely true, because 
the histopathological assessment of macroscopic find-
ings (in the low dose group) as required in Test Guide-
line 408 was obviously not followed”.
Response In contrast to the statement of Bauer-Panskus 
and Then (2014), each gross lesion, as required by the 
OECD Test Guideline 408, was microscopically analysed. 
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III. Bauer-Panskus and Then (2014) argue that the decrease 
in the serum total protein levels could be due to a 
nephrotic syndrome or to an impaired protein synthesis 
in the liver. If the rats were suffering from a nephrotic 
syndrome, oedema and histological alterations of the 
kidneys would be evident. In the experimental groups 
showing a decrease in serum total protein levels, nei-
ther oedema nor histological alterations of the kidneys 
were observed in male rats fed the 33 % GMO diet in 
feeding trial A and in female rats fed the 33 % GMO 
diet in feeding trial B. Furthermore, if protein synthesis 
were impaired, a certain degree of liver parenchymal 
cell death would have become evident, but the histo-
pathological analyses of the liver of male rats fed the 
33 % GMO diet in feeding trial A and in female rats 
fed the 33 % GMO diet in feeding trial B revealed no 
histological alterations.
Based on the above-mentioned facts, we conclude that 
the changes in TP in serum of male rats fed the 11 % GMO 
and 33 % GMO diet in the feeding trial A and in serum of 
female rats fed the 33 % GMO diet in the feeding trial B 
are not related to the feeding of the GMO-containing diets.
3. Bauer-Panskus and Then (2014) state “The second 
inappropriate dismissal involves weight changes of the 
pancreas and blood glucose levels. It is remarkable that 
the authors did not discuss these changes on a physi-
ological level, in spite of the well-known role of the 
pancreas in the regulation of blood glucose levels”.
Response When wanting to analyse the biological/toxi-
cological relevance of the pancreas weight and blood glu-
cose level changes, one should take into account the fol-
lowing facts:
I. The statistically significant decrease in the relative 
pancreas weight of male rats fed the 11 % and 33 % 
GMO diet compared with the control group in the feed-
ing trial A was not dose dependent. Lower pancreas 
weights were also observed in male rats fed the two 
conventional maize varieties in the feeding trial A; in 
the case of the conventional variety 2, the mean value 
was close to those of the two groups fed the GM diets. 
The slightly and not significantly decreased pancreas 
weights of male rats in feeding trial B also showed 
no correlation with the dose, and the mean value for 
the high dose group was practically identical with that 
of one of the groups fed conventional maize. Further-
more, in both trials, there were no significant differ-
ences in the pancreas weights of female rats.
II. The significant increase in the blood glucose levels 
of male rats fed the 11 % and 33 % GMO diet in the 
feeding trial A was not dose dependent. The measured 
blood glucose values were close to those of male rats 
fed the conventional maize varieties. No significant 
differences in blood glucose levels were observed 
between female rats fed the GMO diets in the feeding 
trial A and the corresponding control animals as well 
as between male and female rats fed the GMO diets in 
the feeding trial B and the corresponding control ani-
mals.
III. Considering the potential link between lower pancreas 
weights and elevated glucose levels in male animals, as 
claimed by Bauer-Panskus and Then (2014), it should 
be noted that serum glucose levels are influenced by 
a number of factors. Higher levels may, for exam-
ple, result from feed consumption before sampling 
or stress. In the absence of changes in other relevant 
parameters, they should not be regarded as indicative 
of specific organ toxicity.
IV. In both trials, animals fed the GMO-containing diets 
showed normal body weight development and behav-
iour without any signs of adverse effects. Furthermore, 
no macroscopic lesions or histopathological changes 
were identified in the pancreas.
We conclude that the changes in pancreas weights in 
male animals, which were only significant in trial A and 
not dose dependent, are not toxicologically relevant and not 
related to the feeding of the GMO-containing diets. If one 
takes into account that also the increase in glucose levels in 
male animals in trial A was not dose related and that there 
were no differences at all in the glucose levels between the 
different groups in trial B, the claimed link to an effect on 
the pancreas is unjustified.
As mentioned by Zeljenková et al. (2014) in the Dis-
cussion section, a 1-year feeding study with the MON810-
maize is being performed at the present time by the 
GRACE consortium. Based on the results of the ongoing 
1-year trial with maize MON810, the relevance of the find-
ings in the 90-day feeding trials will again be assessed.
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References
Bauer-Panskus A, Then C (2014) Comments regarding the GRACE 
publication “Ninety-day oral toxicity studies on two geneti-
cally modified maize MON810 varieties in Wistar Han RCC 
139Arch Toxicol (2015) 89:137–139 
1 3
rats (EU 7th Framework Programme project GRACE)”. 
http://www.testbiotech.org/
Zeljenková D, Ambrušová K, Bartušová M, Kebis A, Kovrižnych J, 
Krivošíková Z, Kuricová M, Líšková A, Rollerová E, Spustová 
V, Szabová E, Tulinská J, Wimmerová S, Levkut M, Révajová 
V, Ševcˇíková Z, Schmidt K, Schmidtke J, La Paz JL, Corujo M, 
Pla M, Kleter GA, Kok EJ, Sharbati J, Hanisch C, Einspanier R, 
Adel-Patient K, Wal JM, Spök A, Pöting A, Kohl C, Wilhelm R, 
Schiemann J, Steinberg P (2014) 90-day oral toxicity studies on 
two genetically modified maize MON810 varieties in Wistar Han 
RCC rats (EU 7th Framework Programme project GRACE). Arch 
Toxicol. doi:10.1007/s00204-014-1374-8
